Subscribe
Home
Issues
Online First
2024
February 2024 - Vol 17 No 1
2023
December 2023 - Vol 16 No 6
October 2023 - Vol 16 No 5
August 2023 - Vol 16 No 4
June 2023 - Vol 16 No 3
April 2023 - Vol 16 No 2
February 2023 - Vol 16 No 1
Issue Archive
Special Issues
Supplements
Guide to New FDA Approvals
Categories
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
ONS 2023 - Multiple Myeloma: Wrap-Up
Web Exclusives
OFS Summit
Breast Cancer-OFS Monthly Minutes
Interview with the Innovators
Drug Updates
Media Library
Videos
Rapid Reactions
Audiocasts
Ask the Experts
Master Class Series
Resources
Quick Quiz
CE
Risk factors for chemotherapy toxicity in elderly are identified
Web Exclusives
Wayne Kuznar
CHICAGO—A risk stratification schema can be used to identify older patients who are at risk of grade-3 to -5 toxicity from chemotherapy. The schema includes risk factors based on cancer type, patient age, upfront dose of chemotherapy, the chemotherapeutic regimen used, and history of falling, among others, said Arti Hurria, MD at the 46
th
American Society of Clinical Oncology annual meeting.
“We wanted to develop a predictive model for tolerance to therapy in older adults with cancer,” she said.
To this end, 500 cancer patients 65 years or older from seven institutions completed a prechemotherapy assessment that captured sociodemographic characteristics, tumor characteristics, treatment characteristics, laboratory values, and geriatric assessment parameters. Chemotherapy toxicity was subsequently graded using the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0. Two physicians graded toxicity to adjudicate whether or not the toxicity was due to the chemotherapy. Patients were followed until the end of the chemotherapy regimen.
The geriatric assessment included functional status (including Karnofsky Performance Rating Scale), comorbidity, cognition, psychological status, social functioning, social support, and nutrition (body mass index and the percentage of body weight lost in the past 6 months).
The most common tumor type was lung, in 144 patients, followed by gastrointestinal (137), gynecologic (86), breast (56), urologic (50), and other (27). Sixty percent of the patients had stage IV disease, 70% received polychemotherapy, and 18% received white blood cell growth factor with cycle 1 of treatment.
Almost half (43%) required assistance with instrumental activities of daily living (IADLs), 18% had fallen within the past 6 months, 44% had more than 2 comorbidities, and 38% had weight loss of at least 5% in past 6 months.
“Fifty three percent had grade-3 to -5 toxicity that was adjudicated as being secondary to chemotherapy,” said Hurria, the vast majority being grade-3 toxicity. Grade 3- to -5 hematologic and nonhematologic toxicity occurred in 26% and 43% respectively.
The most common grade-3 to -5 hematologic toxicities were low absolute neutrophil count (11%), low white blood cell count (10%), and low hemoglobin levels (10%); the most common nonhematologic toxicities were fatigue (16%), infection (9%), and dehydration (9%).
On the first model developed (through multivariate analysis), predictors of chemotherapy toxicity were age 73 years or older, gastrointestinal or genitourinary cancers, standard-dose chemotherapy given upfront, receipt of polychemotherapy, falls within the past 6 months, assistance required in IADLs, and decreased social activity.
Individuals with zero to two risk factors had a 34% chance of toxicity, those with three to four risk factors had a 54% chance of toxicity, and those with five to seven risk factors had an 85% risk of toxicity, said Hurria, director of the Cancer and Aging Research Program at City of Hope in Duarte, California.
The first model was then refined through an internal validation process, calibration of the data, and further analysis of individual items in the geriatric assessment measure (to increase ease of administration and scoring), and yielded the following risk factors for grade-3 to -5 toxicity:
Age 73 years or older
Gastrointestinal or genitourinary cancers
Standard-dose chemotherapy
Receipt of polychemotherapy
Low hemoglogin levels (<11 g/dL male; <10 g/dL female)
Low creatinine clearance (Jelliffe-ideal weight <34)
Falls in the past 6 months
Hearing impairment (fair or worse)
Limited in walking one block
Assistance required in medication intake
Decreased social activity
Related Items
HER2-Directed Combination Improves Outcomes in Advanced HER2-Positive Breast Cancer, Including Patients With Brain Metastases
By
Wayne Kuznar
TON - February 2024 Vol 17, No 1
SABCS
Supervised Exercise Program Enhances Quality of Life and Fitness in Patients With Metastatic Breast Cancer
By
Wayne Kuznar
TON - February 2024 Vol 17, No 1
SABCS
,
Breast Cancer
Zanidatamab Demonstrates Durable Antitumor Activity in HER2‑Expressing Gastric Cancers
By
Wayne Kuznar
TON - April 2021 Vol 14, No 2
ASCO
,
Gastrointestinal Cancers
Ivosidenib Extends Survival in Patients with Cholangiocarcinoma and IDH1 Mutation
By
Wayne Kuznar
TON - April 2021 Vol 14, No 2
ASCO
Surgery Is a Viable Treatment Option for Patients with Early-Stage Germ Cell Tumors
By
Wayne Kuznar
TON - June 2020, Vol 13, No 3
Survivorship
Encorafenib plus Cetuximab Improves Quality of Life versus Standard of Care in Colorectal Cancer Associated with BRAF Mutation By Wayne Kuznar
By
Wayne Kuznar
TON - June 2020, Vol 13, No 3
Colorectal Cancer
Universal CAR T-Cells a Promising Off-the-Shelf Therapy for T-Cell Acute Lymphoblastic Leukemia
By
Wayne Kuznar
TON - June 2020, Vol 13, No 3
AACR Highlights
Gemcitabine-Cisplatin Combination a New Standard in Pancreatic Cancer with Germline BRCA or PALB2 Mutation
By
Wayne Kuznar
TON - June 2020, Vol 13, No 3
Pancreatic Cancer
NCCN Issues Guidance for Cancer Care During the COVID-19 Pandemic
By
Wayne Kuznar
TON - June 2020, Vol 13, No 3
COVID-19
The Pediatric MATCH Study: Actionable Targets Found in 25% of Young Patients with Cancer
By
Wayne Kuznar
TON - October 2019, Vol 12, No 5
Pediatric Cancer
View the Latest Issue of TON
Read Issue
Home
Issues
Online First
2024
February 2024 - Vol 17 No 1
2023
December 2023 - Vol 16 No 6
October 2023 - Vol 16 No 5
August 2023 - Vol 16 No 4
June 2023 - Vol 16 No 3
April 2023 - Vol 16 No 2
February 2023 - Vol 16 No 1
Issue Archive
Special Issues
Supplements
Guide to New FDA Approvals
Categories
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
ONS 2023 - Multiple Myeloma: Wrap-Up
Web Exclusives
OFS Summit
Breast Cancer-OFS Monthly Minutes
Interview with the Innovators
Drug Updates
Media Library
Videos
Rapid Reactions
Audiocasts
Ask the Experts
Master Class Series
Resources
Quick Quiz
CE
Subscribe Today!
To sign up for our newsletter or print publications, please enter your contact information below.
I'd like to receive:
TON
Print Edition
TON
Weekly e‑Newsletter
-- Please Select --
Afghanistan
Åland Islands
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica
Antigua and Barbuda
Argentina
Armenia
Aruba
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia, Plurinational State of
Bonaire, Sint Eustatius and Saba
Bosnia and Herzegovina
Botswana
Bouvet Island
Brazil
British Indian Ocean Territory
Brunei Darussalam
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Cape Verde
Cayman Islands
Central African Republic
Chad
Chile
China
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Congo
Congo, the Democratic Republic of the
Cook Islands
Costa Rica
Côte d'Ivoire
Croatia
Cuba
Curaçao
Cyprus
Czech Republic
Denmark
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland Islands (Malvinas)
Faroe Islands
Fiji
Finland
France
French Guiana
French Polynesia
French Southern Territories
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guernsey
Guinea
Guinea-Bissau
Guyana
Haiti
Heard Island and McDonald Islands
Holy See (Vatican City State)
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran, Islamic Republic of
Iraq
Ireland
Isle of Man
Israel
Italy
Jamaica
Japan
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Korea, Democratic People's Republic of
Korea, Republic of
Kuwait
Kyrgyzstan
Lao People's Democratic Republic
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macao
Macedonia, the former Yugoslav Republic of
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte
Mexico
Micronesia, Federated States of
Moldova, Republic of
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
New Caledonia
New Zealand
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestinian Territory, Occupied
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn
Poland
Portugal
Puerto Rico
Qatar
Réunion
Romania
Russian Federation
Rwanda
Saint Barthélemy
Saint Helena, Ascension and Tristan da Cunha
Saint Kitts and Nevis
Saint Lucia
Saint Martin (French part)
Saint Pierre and Miquelon
Saint Vincent and the Grenadines
Samoa
San Marino
Sao Tome and Principe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Singapore
Sint Maarten (Dutch part)
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Georgia and the South Sandwich Islands
South Sudan
Spain
Sri Lanka
Sudan
Suriname
Svalbard and Jan Mayen
Swaziland
Sweden
Switzerland
Syrian Arab Republic
Taiwan, Province of China
Tajikistan
Tanzania, United Republic of
Thailand
Timor-Leste
Togo
Tokelau
Tonga
Trinidad and Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States
United States Minor Outlying Islands
Uruguay
Uzbekistan
Vanuatu
Venezuela, Bolivarian Republic of
Viet Nam
Virgin Islands, British
Virgin Islands, U.S.
Wallis and Futuna
Western Sahara
Yemen
Zambia
Zimbabwe
I have reviewed and consent to the terms of
TON
's
Privacy Policy
, and
TON
has my permission to retain my information in its database, and to forward pertinent communications to me.
START YOUR SUBSCRIPTION